Updates are available Correction dated 2023-08-10
Click to view Correction: https://doi.org/10.1038/s41590-023-01611-0
-
Authors
Liu, Pu-Ste https://orcid.org/0000-0003-1429-3791
Chen, Yi-Ting
Li, Xiaoyun
Hsueh, Pei-Chun
Tzeng, Sheue-Fen https://orcid.org/0000-0003-1126-6763
Chen, Hsi
Shi, Pei-Zhu
Xie, Xin https://orcid.org/0000-0002-6784-4860
Parik, Sweta https://orcid.org/0000-0002-7801-7086
Planque, Mélanie https://orcid.org/0000-0001-7052-7084
Fendt, Sarah-Maria https://orcid.org/0000-0001-6018-9296
Ho, Ping-Chih https://orcid.org/0000-0003-3078-3774
- License Information
-
More Information
Article History
Received: 3 June 2022
Accepted: 9 January 2023
First Online: 23 February 2023
Change Date: 10 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41590-023-01611-0
Competing interests
: S.-M.F. received funding from Bayer, Merck, Alesta Therapeutics, Gilead and Black Belt Therapeutics and serves on the scientific advisory board for Alesta Therapeutics. P.-C. Ho serves as scientific advisor for Elixiron Immunotherapeutics and co-funder for Pilatus Biosciences. The other authors declare no competing interests.
